Coherus Oncology, Inc. (CHRS) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
CHRS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CHRS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | -37.3% | -429.5% | 398.4% |
| 2024 | 56.0% | -41.8% | 10.7% |
| 2023 | 38.2% | -79.0% | -92.5% |
| 2022 | 66.8% | -121.7% | -138.2% |
| 2021 | 82.4% | -80.8% | -87.9% |
Download Data
Export CHRS earnings history in CSV or JSON format
Free sign-in required to download data
Coherus Oncology, Inc. (CHRS) Earnings Overview
As of May 8, 2026, Coherus Oncology, Inc. (CHRS) reported trailing twelve-month net income of $168M, reflecting +472.0% year-over-year growth. The company earned $1.40 per diluted share over the past four quarters, with a net profit margin of 398.4%.
Looking at the long-term picture, CHRS's 5-year EPS compound annual growth rate (CAGR) stands at -2.5%, signaling declining earnings. The company achieved its highest annual net income of $168M in fiscal 2025, representing a new all-time high.
Coherus Oncology, Inc. maintains industry-leading profitability with a gross margin of -37.3%, operating margin of -429.5%, and net margin of 398.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including PRGO (-$1.82B net income, -33.5% margin), AMRX ($72M net income, 2.4% margin), HCM ($467M net income, 6.0% margin), CHRS has outperformed on profitability metrics. Compare CHRS vs PRGO →
CHRS Earnings vs Peers
Earnings metrics vs comparable public companies
CHRS Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $168M | +489.4% | -$181M | $1.43 | 398.4% | -429.5% |
| 2024 | $29M | +112.0% | -$112M | $0.25 | 10.7% | -41.8% |
| 2023 | -$238M | +18.5% | -$203M | $-2.53 | -92.5% | -79.0% |
| 2022 | -$292M | -1.6% | -$257M | $-3.76 | -138.2% | -121.7% |
| 2021 | -$287M | -317.1% | -$264M | $-3.81 | -87.9% | -80.8% |
| 2020 | $132M | +47.2% | $156M | $1.62 | 27.8% | 32.9% |
| 2019 | $90M | +142.9% | $108M | $1.23 | 25.2% | 30.3% |
| 2018 | -$209M | +12.1% | -$204M | $-3.22 | -13453.7% | -13137.3% |
| 2017 | -$238M | -87.0% | -$232M | $-4.48 | -15306.6% | -14918.8% |
| 2016 | -$127M | +43.0% | -$116M | $-3.04 | -67.0% | -61.0% |
See CHRS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CHRS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CHRS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCHRS — Frequently Asked Questions
Quick answers to the most common questions about buying CHRS stock.
Is CHRS growing earnings?
CHRS EPS is $1.40, with earnings growth accelerating to +472.0%. This exceeds the 5-year CAGR of -2.5%. TTM net income reached $168M.
What are CHRS's profit margins?
Coherus Oncology, Inc. net margin is +398.4%, with operating margin at -429.5%. Above-average margins indicate pricing power.
How consistent are CHRS's earnings?
CHRS earnings data spans 2012-2025. The accelerating earnings trend is +472.0% YoY. Historical data enables comparison across business cycles.